Patent ID: 11944644
Assignee: THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 8:
9. The T-cell of claim 8, wherein the DNA construct is characterized by at least one of:
(i) the leader peptide has the amino acid sequence of SEQ ID NO: 20;
(ii) the activation domain has the amino acid sequence of SEQ ID NO: 23;
(iii) the costimulatory domain has the amino acid sequence of SEQ ID NO: 22;
(iv) the anti-CD138 scFv domain has the amino acid sequence of SEQ ID NO: 18;
(v) the anti-CD38 scFv domain has the amino acid sequence of SEQ ID NO: 19;
(vi) the self-cleaving peptide is selected from the peptide having the amino acid sequence of SEQ ID NO: 26, IRES peptide;
(vii) the leader peptide is encoded by the DNA sequence set forth in SEQ ID NO: 39;
(viii) the anti-CD138 scFv is encoded by the DNA sequence set forth in SEQ ID NO: 28;
(ix) the anti-CD38 scFv is encoded by the DNA sequence set forth in SEQ ID NO: 29;
(x) the costimulatory domain is encoded by the DNA sequence set forth in SEQ ID NO: 30; and
(xi) the activation domain is encoded by the DNA sequence set forth in SEQ ID NO: 31.